Soterios Topical Could Take On JAK Class In Alopecia Areata

The UK biotech unveils Phase II data showing an ability to reduce severity of mild-to-moderate AA, with full hair restoration in some patients. If approved, STS-01 will compete with Olumiant and Litfulo.

Front view of a balding woman before and after hair treatment. Divided image of the head. Two halves. Sticker revealing healthy scalp. Female alopecia. Isolated vector illustration.
Soterios wants to compete against JAK inhibitors in alopecia areata

More from Clinical Trials

More from R&D